56.97
0.26%
-0.15
Incyte Corp. stock is currently priced at $56.97, with a 24-hour trading volume of 1.88M.
It has seen a -0.26% decreased in the last 24 hours and a -5.02% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $56.99 pivot point. If it approaches the $56.63 support level, significant changes may occur.
Incyte Corp. Stock (INCY) Financials Data
Incyte Corp. (INCY) Revenue 2023
INCY reported a revenue (TTM) of $3.70 billion for the quarter ending December 31, 2023, a +8.87% rise year-over-year.
Incyte Corp. (INCY) Net Income 2023
INCY net income (TTM) was $597.60 million for the quarter ending December 31, 2023, a +75.42% increase year-over-year.
Incyte Corp. (INCY) Cash Flow 2023
INCY recorded a free cash flow (TTM) of $449.00 million for the quarter ending December 31, 2023, a -49.67% decrease year-over-year.
Incyte Corp. (INCY) Earnings per Share 2023
INCY earnings per share (TTM) was $2.65 for the quarter ending December 31, 2023, a +74.34% growth year-over-year.
Incyte Corp. Stock (INCY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Iyengar Vijay K | EVP, GMAPPS |
Jan 02 '24 |
Sale |
65.00 |
657 |
42,705 |
43,412 |
Tray Thomas | Principal Accounting Officer |
Dec 13 '23 |
Sale |
62.37 |
1,067 |
66,549 |
23,436 |
Tray Thomas | Principal Accounting Officer |
Dec 12 '23 |
Sale |
57.36 |
210 |
12,046 |
24,503 |
SWAIN PAULA J | EVP, Human Resources |
Sep 01 '23 |
Sale |
65.13 |
8,449 |
550,283 |
77,530 |
Stein Steven H | EVP & Chief Medical Officer |
Aug 01 '23 |
Sale |
63.28 |
21,511 |
1,361,216 |
97,583 |
Incyte Corp. Stock (INCY) Latest News
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Zacks Investment Research
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
Zacks Investment Research
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Zacks Investment Research
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Benzinga
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Zacks Investment Research
About Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Cap:
|
Volume (24h):